Cargando…

Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study

It has not yet been determined whether chronic exposure to relatively low doses of pioglitazone increases risk of bladder cancer. We aimed to assess the risk of bladder cancer associated with pioglitazone in Korean patients. This was a retrospective cohort study of diabetic patients who had ≥ 2 clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Sang-Man, Song, Sun Ok, Jung, Chang Hee, Chang, Jin-Sun, Suh, Sunghwan, Kang, Seung Min, Jung, Inkyung, Park, Cheol-Young, Kim, Jae Hyeon, Cho, Jae Hyoung, Lee, Byung-Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924003/
https://www.ncbi.nlm.nih.gov/pubmed/24550651
http://dx.doi.org/10.3346/jkms.2014.29.2.238
_version_ 1782303687995031552
author Jin, Sang-Man
Song, Sun Ok
Jung, Chang Hee
Chang, Jin-Sun
Suh, Sunghwan
Kang, Seung Min
Jung, Inkyung
Park, Cheol-Young
Kim, Jae Hyeon
Cho, Jae Hyoung
Lee, Byung-Wan
author_facet Jin, Sang-Man
Song, Sun Ok
Jung, Chang Hee
Chang, Jin-Sun
Suh, Sunghwan
Kang, Seung Min
Jung, Inkyung
Park, Cheol-Young
Kim, Jae Hyeon
Cho, Jae Hyoung
Lee, Byung-Wan
author_sort Jin, Sang-Man
collection PubMed
description It has not yet been determined whether chronic exposure to relatively low doses of pioglitazone increases risk of bladder cancer. We aimed to assess the risk of bladder cancer associated with pioglitazone in Korean patients. This was a retrospective cohort study of diabetic patients who had ≥ 2 clinic visits between November 2005 and June 2011 at one of four tertiary referral hospitals in Korea. A prevalent case-control analysis nested within the cohort was conducted to further adjust confounders. A total of 101,953 control patients and 11,240 pioglitazone-treated patients were included, in which there were 237 and 30 cases of incidental bladder cancer (64.9 and 54.9 per 100,000 person-years; age, sex-adjusted HR 1.135, 95% confidence interval [CI] 0.769-1.677), respectively. In the prevalent case-control analysis nested within the cohort, use of pioglitazone for a duration of > 6 months, but not ever use of pioglitazone, was associated with an increased rate of bladder cancer as compared to never use of pioglitazone. In conclusion, we failed to exclude the possible association between use of pioglitazone for a duration of > 6 months and bladder cancer. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-3924003
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-39240032014-02-18 Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study Jin, Sang-Man Song, Sun Ok Jung, Chang Hee Chang, Jin-Sun Suh, Sunghwan Kang, Seung Min Jung, Inkyung Park, Cheol-Young Kim, Jae Hyeon Cho, Jae Hyoung Lee, Byung-Wan J Korean Med Sci Original Article It has not yet been determined whether chronic exposure to relatively low doses of pioglitazone increases risk of bladder cancer. We aimed to assess the risk of bladder cancer associated with pioglitazone in Korean patients. This was a retrospective cohort study of diabetic patients who had ≥ 2 clinic visits between November 2005 and June 2011 at one of four tertiary referral hospitals in Korea. A prevalent case-control analysis nested within the cohort was conducted to further adjust confounders. A total of 101,953 control patients and 11,240 pioglitazone-treated patients were included, in which there were 237 and 30 cases of incidental bladder cancer (64.9 and 54.9 per 100,000 person-years; age, sex-adjusted HR 1.135, 95% confidence interval [CI] 0.769-1.677), respectively. In the prevalent case-control analysis nested within the cohort, use of pioglitazone for a duration of > 6 months, but not ever use of pioglitazone, was associated with an increased rate of bladder cancer as compared to never use of pioglitazone. In conclusion, we failed to exclude the possible association between use of pioglitazone for a duration of > 6 months and bladder cancer. GRAPHICAL ABSTRACT: [Image: see text] The Korean Academy of Medical Sciences 2014-02 2014-01-28 /pmc/articles/PMC3924003/ /pubmed/24550651 http://dx.doi.org/10.3346/jkms.2014.29.2.238 Text en © 2014 The Korean Academy of Medical Sciences. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jin, Sang-Man
Song, Sun Ok
Jung, Chang Hee
Chang, Jin-Sun
Suh, Sunghwan
Kang, Seung Min
Jung, Inkyung
Park, Cheol-Young
Kim, Jae Hyeon
Cho, Jae Hyoung
Lee, Byung-Wan
Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study
title Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study
title_full Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study
title_fullStr Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study
title_full_unstemmed Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study
title_short Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study
title_sort risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in korea: a multi-center retrospective cohort study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924003/
https://www.ncbi.nlm.nih.gov/pubmed/24550651
http://dx.doi.org/10.3346/jkms.2014.29.2.238
work_keys_str_mv AT jinsangman riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy
AT songsunok riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy
AT jungchanghee riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy
AT changjinsun riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy
AT suhsunghwan riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy
AT kangseungmin riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy
AT junginkyung riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy
AT parkcheolyoung riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy
AT kimjaehyeon riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy
AT chojaehyoung riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy
AT leebyungwan riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy